Krebs Biochemicals & Industries Limited (BOM:524518)
75.85
+3.10 (4.26%)
At close: Sep 10, 2025
BOM:524518 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 359.04 | 433.12 | 504.22 | 521.34 | 597.03 | 386.06 | Upgrade |
Other Revenue | - | - | - | - | - | 140.77 | Upgrade |
359.04 | 433.12 | 504.22 | 521.34 | 597.03 | 526.84 | Upgrade | |
Revenue Growth (YoY) | -31.91% | -14.10% | -3.29% | -12.68% | 13.32% | 62.63% | Upgrade |
Cost of Revenue | 45.87 | 100.31 | 93.99 | 277.16 | 441.18 | 515.96 | Upgrade |
Gross Profit | 313.17 | 332.81 | 410.23 | 244.19 | 155.85 | 10.87 | Upgrade |
Selling, General & Admin | 151.01 | 172.59 | 170.53 | 165.32 | 159.81 | 167.75 | Upgrade |
Other Operating Expenses | 304.5 | 306.24 | 323.98 | 231.74 | 328.01 | 12.6 | Upgrade |
Operating Expenses | 521.48 | 545.72 | 562.17 | 462.65 | 550.79 | 232.39 | Upgrade |
Operating Income | -208.31 | -212.91 | -151.95 | -218.46 | -394.94 | -221.52 | Upgrade |
Interest Expense | -62.46 | -59.08 | -46.86 | -29.71 | -53.85 | -62.72 | Upgrade |
Interest & Investment Income | - | 1.59 | 1.56 | 1.27 | 3.58 | 0.72 | Upgrade |
Other Non Operating Income (Expenses) | 0 | -0.06 | -0.04 | -0.02 | -0.06 | -0.07 | Upgrade |
EBT Excluding Unusual Items | -270.77 | -270.46 | -197.28 | -246.92 | -445.27 | -283.59 | Upgrade |
Gain (Loss) on Sale of Assets | - | 1.22 | - | - | - | - | Upgrade |
Pretax Income | -270.77 | -269.24 | -197.28 | -246.92 | -445.27 | -283.59 | Upgrade |
Income Tax Expense | 0.15 | 0.15 | - | - | - | - | Upgrade |
Net Income | -270.93 | -269.39 | -197.28 | -246.92 | -445.27 | -283.59 | Upgrade |
Net Income to Common | -270.93 | -269.39 | -197.28 | -246.92 | -445.27 | -283.59 | Upgrade |
Shares Outstanding (Basic) | 22 | 22 | 22 | 22 | 22 | 20 | Upgrade |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 22 | 22 | 20 | Upgrade |
Shares Change (YoY) | 0.21% | - | - | - | 9.89% | 9.00% | Upgrade |
EPS (Basic) | -12.56 | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 | Upgrade |
EPS (Diluted) | -12.56 | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 | Upgrade |
Free Cash Flow | - | -114.54 | -70.5 | -398.71 | -442.95 | -400.81 | Upgrade |
Free Cash Flow Per Share | - | -5.31 | -3.27 | -18.49 | -20.54 | -20.43 | Upgrade |
Gross Margin | 87.22% | 76.84% | 81.36% | 46.84% | 26.11% | 2.06% | Upgrade |
Operating Margin | -58.02% | -49.16% | -30.14% | -41.90% | -66.15% | -42.05% | Upgrade |
Profit Margin | -75.46% | -62.20% | -39.13% | -47.36% | -74.58% | -53.83% | Upgrade |
Free Cash Flow Margin | - | -26.45% | -13.98% | -76.48% | -74.19% | -76.08% | Upgrade |
EBITDA | -141.15 | -147.86 | -86.12 | -154.71 | -338.36 | -172.88 | Upgrade |
EBITDA Margin | -39.31% | -34.14% | -17.08% | -29.68% | -56.67% | -32.81% | Upgrade |
D&A For EBITDA | 67.16 | 65.05 | 65.82 | 63.75 | 56.58 | 48.64 | Upgrade |
EBIT | -208.31 | -212.91 | -151.95 | -218.46 | -394.94 | -221.52 | Upgrade |
EBIT Margin | -58.02% | -49.16% | -30.14% | -41.90% | -66.15% | -42.05% | Upgrade |
Revenue as Reported | 365.91 | 440.21 | 508.73 | 527.55 | 608.59 | 543.22 | Upgrade |
Advertising Expenses | - | - | - | - | - | 0.05 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.